SITC Meeting

A personalized neoantigen-specific and off-the-shelf T cell receptor T-cell therapy utilized through CRISPR gene editing technology demonstrated feasibility and tolerability in 16 patients across multiple tumor types, according to first-in-human phase 1a findings.

The addition of ramucirumab to pembrolizumab elicited an encouraging response rate when used in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.

Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.

Kim A. Reiss Binder, MD, discusses the initial results of a phase 1 trial, which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors.

Myrto Moutafi, MD, MSc, discusses the results of a study evaluating biomarkers of resistance in non–small cell lung cancer.

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Hans Wildiers, MD, medical oncologist, Department of Medical Oncology, full professor, Faculty of Medicine, member, Laboratory of Experimental Oncology, University Hospital Leuven, Leuven, Belgium, discusses the final results of the phase 2b AIPAC trial (NCT02614833) in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Jonathan D. Cheng, MD, discusses advances with immunotherapy-based combinations in oncology.

Concurrent treatment with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia who were receiving lisocabtagene maraleucel led to measurable effects in both CAR+ and endogenous T cells, both of which were linked with improved efficacy.

The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096).

ICT01, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9δ2 T cells, has demonstrated early signs of biological activity when given as a single agent or in combination with pembrolizumab in patients with advanced solid tumors.

The combination of eftilagimod alpha and paclitaxel produced a modest increase in median overall survival in patients with endocrine-resistant hormone receptor–positive/HER2-negative metastatic breast cancer. Though, the effects were significant in patients younger than 65 years old, had low monocytes, or had more aggressive disease.

ATG-101, a novel PD-L1/4-1BB bispecific antibody, demonstrated good in vivo efficacy, safety without hepatotoxicity, and pharmacokinetic/pharmacodynamic properties in cynomolgus monkeys.

The innate cell engager AFM24 showed greater efficacy in eliciting antibody-dependent cellular phagocytosis of EGFR wild-type and KRAS-mutant tumor cells compared with cetuximab.

The DuoBody®-CD3x5T4 was found to induce secretion of granzyme B and efficiently kill tumor cells in co-cultures of healthy donor T cells and patient-derived head and neck squamous cell carcinoma cell lines.

November 13, 2020 - The combination of nivolumab and ipilimumab elicited an objective response rate of 25% and was found to be well tolerated in patients with advanced or unresectable angiosarcoma, according to cohort findings of the phase 2 DART trial.

November 13, 2020 - In an effort to expand the benefit of immunotherapy to nonresponders or those who have relapsed, the novel STING agonist SB 11285 is being evaluated as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors in a phase 1/1b dose-escalation trial.

November 13, 2020 - The addition of plasmid IL-12 pembrolizumab resulted in durable responses, as well as several complete responses, in patients with advanced melanoma who were refractory to PD-1–directed therapy.

Matthew T. Campbell, MD, MS, discusses the expanding role of cabozantinib in renal cell carcinoma.

Thomas Hutson, DO, PharmD, discusses remaining questions regarding the durability of responses to immunotherapy in patients with renal cell carcinoma.

Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.

November 12, 2020 — Pembrolizumab led to a 38% central nervous system response rate and was well tolerated in patients with leptomeningeal metastasis from solid tumors. However, the study was closed early due to poor accrual.

November 12, 2020 - The investigational PD-L1 inhibitor cosibelimab demonstrated durable and robust responses in patients with non–small cell lung cancer and cutaneous squamous cell carcinoma.

November 12, 2020 - The combination of CMP-001 intratumoral injection and pembrolizumab was found to reverse PD-1 blockade resistance and elicit durable systemic responses in patients with advanced melanoma.

November 12, 2020 - Cemiplimab demonstrated clinically meaningful antitumor activity, including durable responses, and acceptable safety in patients with metastatic basal cell carcinoma after progression on or intolerance to hedgehog inhibitors

David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses IPI-549 during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

The combination of cabiralizumab and nivolumab resulted in intriguing objective response rates in heavily pretreated patients with metastatic pancreatic cancer.